; and (III) any other information determined appropriate by the Secretary. (v) Limited access drug defined In this subparagraph, the term limited access drug means a covered part D drug that meets at least one of the following: (I) The Food and Drug Administration has restricted distribution of such covered part D drug to certain facilities or physicians. (II) The dispensing of such covered part D drug requires extraordinary special handling, provider coordination, or patient education that cannot be met by a network pharmacy. . (vii) Implementation Notwithstanding any other provision of law, the Secretary shall implement this subparagraph by program instruction or otherwise. (viii) Nonapplication of paperwork reduction act Chapter 35 of title 44, United States Code, shall not apply to any data collection undertaken by the Secretary under this subparagraph. . 12. Beneficiary-focused listening sessions to improve prescription drug plan transparency, access, and choice Section 1860D–42 of the Social Security Act ( 42 U.S.C. 1395w–152 ), as amended by section 7, is amended by adding at the end the following new subsection: (f) Beneficiary-focused listening sessions to improve prescription drug plan transparency, access, and choice (1) In general Not later than December 31, 2024, the Secretary shall hold at least one beneficiary-focused listening session to receive input on potential improvements to the experience with, and transparency of, prescription drug plans under this part, as described in paragraph (2). (2) Beneficiary-focused listening sessions Any beneficiary-focused listening session held under paragraph (1) shall be open to the public, including beneficiaries, caregivers of beneficiaries, consumer and patient advocacy organizations, health care providers, and other interested parties. Any such listening sessions may include an opportunity for the public to provide input to the Secretary on potential improvements to— (A) the information made available by prescription drug plans to individuals